Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roger Paredes

Showing results (251-260 of 309) with videos related to

Pageof 31
Sort By:
Clinical and Translational Science|February 5, 2026
Effects of Siltuximab Versus Corticosteroids in Preventing COVID-19 Pneumonia Disease Progression: Multicentre, Open-Label, Randomized Clinical TrialLorna Leal, María Del Puerto Bernoy González, Clara Castán, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|November 20, 2023
Vagus nerve dysfunction in the post-COVID-19 condition: a pilot cross-sectional studyGemma Lladós, Marta Massanella, Roser Coll-Fernández, et al.
Med (New York, N.Y.)|February 8, 2021
Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodesEdwards Pradenas, Benjamin Trinité, Víctor Urrea, et al.
Frontiers in Microbiology|April 12, 2019
Earlier Initiation of Antiretroviral Treatment Coincides With an Initial Control of the HIV-1 Sub-Subtype F1 Outbreak Among Men-Having-Sex-With-Men in Flanders, BelgiumLore Vinken, Katrien Fransen, Lize Cuypers, et al.
Viruses|June 26, 2026
Optimizing HIV-1 Genotypic Resistance Testing for Low- and Middle-Income Countries: High-Impact HIV-1 Mutations Across WHO-Defined ScenariosRobert W Shafer, Kaiming Tao, Tom Loosli, et al.
Nature Medicine|October 27, 2022
Safety, immunogenicity and effect on viral rebound of HTI vaccines in early treated HIV-1 infection: a randomized, placebo-controlled phase 1 trialLucia Bailón, Anuska Llano, Samandhy Cedeño, et al.
Mucosal Immunology|September 2, 2018
Low nadir CD4+ T-cell counts predict gut dysbiosis in HIV-1 infectionYolanda Guillén, Marc Noguera-Julian, Javier Rivera, et al.
Antibiotics (Basel, Switzerland)|April 27, 2026
Retrospective Analysis of the Epidemiology and Risk Factors for Recurrent Biliary-Source Bloodstream Infections in Oncologic PatientsPaola Maffezzoli, Ignacio Grafia, Mar Cusó Banús, et al.
The Journal of Antimicrobial Chemotherapy|October 23, 2014
Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case-control study using centralized ultrasensitive 454 pyrosequencingAlessandro Cozzi-Lepri, Marc Noguera-Julian, Francesca Di Giallonardo, et al.
Viruses|July 2, 2020
Multi-Laboratory Comparison of Next-Generation to Sanger-Based Sequencing for HIV-1 Drug Resistance GenotypingNeil T Parkin, Santiago Avila-Rios, David F Bibby, et al.
Pageof 31

Showing results (251-260 of 309) with videos related to

Sort By:
Pageof 31
Clinical and Translational Science|February 5, 2026
Effects of Siltuximab Versus Corticosteroids in Preventing COVID-19 Pneumonia Disease Progression: Multicentre, Open-Label, Randomized Clinical TrialLorna Leal, María Del Puerto Bernoy González, Clara Castán, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|November 20, 2023
Vagus nerve dysfunction in the post-COVID-19 condition: a pilot cross-sectional studyGemma Lladós, Marta Massanella, Roser Coll-Fernández, et al.
Med (New York, N.Y.)|February 8, 2021
Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodesEdwards Pradenas, Benjamin Trinité, Víctor Urrea, et al.
Frontiers in Microbiology|April 12, 2019
Earlier Initiation of Antiretroviral Treatment Coincides With an Initial Control of the HIV-1 Sub-Subtype F1 Outbreak Among Men-Having-Sex-With-Men in Flanders, BelgiumLore Vinken, Katrien Fransen, Lize Cuypers, et al.
Viruses|June 26, 2026
Optimizing HIV-1 Genotypic Resistance Testing for Low- and Middle-Income Countries: High-Impact HIV-1 Mutations Across WHO-Defined ScenariosRobert W Shafer, Kaiming Tao, Tom Loosli, et al.
Nature Medicine|October 27, 2022
Safety, immunogenicity and effect on viral rebound of HTI vaccines in early treated HIV-1 infection: a randomized, placebo-controlled phase 1 trialLucia Bailón, Anuska Llano, Samandhy Cedeño, et al.
Mucosal Immunology|September 2, 2018
Low nadir CD4+ T-cell counts predict gut dysbiosis in HIV-1 infectionYolanda Guillén, Marc Noguera-Julian, Javier Rivera, et al.
Antibiotics (Basel, Switzerland)|April 27, 2026
Retrospective Analysis of the Epidemiology and Risk Factors for Recurrent Biliary-Source Bloodstream Infections in Oncologic PatientsPaola Maffezzoli, Ignacio Grafia, Mar Cusó Banús, et al.
The Journal of Antimicrobial Chemotherapy|October 23, 2014
Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case-control study using centralized ultrasensitive 454 pyrosequencingAlessandro Cozzi-Lepri, Marc Noguera-Julian, Francesca Di Giallonardo, et al.
Viruses|July 2, 2020
Multi-Laboratory Comparison of Next-Generation to Sanger-Based Sequencing for HIV-1 Drug Resistance GenotypingNeil T Parkin, Santiago Avila-Rios, David F Bibby, et al.
Pageof 31